Although PD-L1 expression on tumor cells appears to be ideal for determining the efficacy of an anti-PD-1/PD-L1 therapy, its predictive quality is under debate, presumably due to various other factors that contribute to the immunosuppressive environment on an individual tumor. The gene discussed is CD274; the disease is neoplasm.